Chiara Lazzari, Alessandra Bulotta, Monika Ducceschi, Maria Grazia Viganò, Elena Brioschi, Francesca Corti, Luca Gianni, Vanesa Gregorc
Abstract
Innovative therapeutic agents have significantly improved outcome with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, who depend on oncogenic molecular alterations for their malignant phenotype. Despite the survival improvement achieved with first-line chemotherapy, about 30% of patients do not obtain a tumor response. Moreover, those patients, initially sensitive to treatment, acquire resistance and develop tumor progression after a median of about 5 months. Approximately 60% of the patients progressing from first-line chemotherapy receive further systemic treatment in the second-line setting. Moreover, new options have emerged in the second-line armamentarium for the treatment of patients with NSCLC, including immune checkpoint inhibitors and antiangiogenic agents. The current review provides an overview on the clinical studies that gained the approval of chemotherapy agents (docetaxel and pemetrexed) and epidermal growth factor receptor gene-tyrosine kinase inhibitors as second-line treatment options for NSCLC patients, not carrying molecular alterations.
Pharmacology, Toxicology and Pharmaceutical Science
3
7%
Environmental Science
2
5%
Neuroscience
2
5%
Other
2
5%
Unknown
13
31%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2023.
All research outputs
#3,442,966
of 24,677,985 outputs
Outputs from Frontiers in Medicine
#946
of 6,791 outputs
Outputs of similar age
#67,856
of 428,257 outputs
Outputs of similar age from Frontiers in Medicine
#6
of 36 outputs
Altmetric has tracked 24,677,985 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,791 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.9. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 428,257 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.
